Some people were apparently surprised that Eli Lilly has emerged as the mystery $70-a-share bidder for ImClone. BNET readers weren’t among them, as I noted a few days ago this is just the kind of bold plan that CEO John Lechleiter seems to favor. Interestingly, ImClone’s stock has hovered around the $65-$66 level all day, suggesting that there’s a few people out there who...
Pharma Industry Archive
October 2008
The future for branded antidepressants as a business looks grim. Here’s the current patent expiration schedule for the four biggest sellers: GlaxoSmithKline’s Paxil CR expires in 2008 Wyeth’s Effexor XR expires in 2011 Forest Labs‘ Lexapro expires in 2012 Eli Lilly’s Cymbalta expires in 2014 With these massive revenue streams set to come to an end, expect drug...
Florida suing Merck over “deceptive” Vioxx marketing — The Sunshine State has become the ninth to file a lawsuit against Merck, seeking damages for the $80 million the state’s Medicaid program spent on the drug before its potentially dangerous side effects came to light. [Source: WSJ Health Blog] Credit woes squeeze European biotech — The credit crisis will likely...
Another page has been torn off the calendar, and that means it’s time to open up Big Pharma’s vault of peculiarities and do a roundup of strange-but-true tales from the world of drugs that surfaced on my radar last month. I give you the 10 weirdest drug stories of September: Bristol-Myers Squibb gets out of the airline business For 40 years the drug company has operated its own...
While the antidepressant market is both robust and lucrative, as we saw in part 1 of this three-part series, it is also controversial. No drug category is so dogged by doubts and questions, and yet so widely prescribed, as antidepressants. The most recent major event in the antidepressant news cycle was the FDA’s decision to publish a list of drugs associated with concerns that they may,...
- Novartis Looks at Combination Pills to Fix Hypertension Franchise
- Study Showing Drug Ads Are Linked to Higher Prices Has Flaws
- Bankers Reveal Top Biotech IPO Contenders; New Filer Ironwood Among Them
- Pfizer Got $160M in Tax Money to Build in Connecticut
- Sanofi's Viehbacher Backs Health Reform; May Change Company's Name
- Viagra Now Available Intravenously
- Genzyme Kidney Drug Failed, Too...What Could Possibly Happen Next?
- Peter Pitts' CMPI Targeted Over Anti-Healthcare Reform Video Game
- Why Allergan and Medicis Should Embrace the "Botox Tax" in Senate Health Bill
- Why J&J's Stelara Launch Should Target Dermatologists First
- NHS Loses Fight Over Publication of Antipsychotic Meds Brochures for Kids
- Genzyme's Termeer Got $50M in Compensation Over Last 3 Years; Wife Got Trips to Asia on Corporate Jet
- Merck Gives Snapshot of Combined Company: $47B in Sales; Just $7.6B in Cash
- Why Pfizer Wants Your Car-Sick Dog to Travel on Thanksgiving
- FDA Delays Genzyme's Lumizyme, Manufacturing Problems Blamed
- Will FDA Approve MannKind's Insulin Inhaler?
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
- Hepatitis C Drugs Kill the Virus...and Your Sex Drive
- Microchip Implant to Link Your Health Records, Credit History, Social Security
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
- NYT's MannKind Story Needlessly Quoted a Competitor Bashing Afresa
- Novartis CEO Sends Emails to 140 Animal Rights Activists:
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low
Subscribe to Pharma blog comments RSS 
- How NOT to Write a Biotech Press Release: Just Ask Epeius
- The 10 Weirdest Drug Stories of the Month
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity"
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
Industry Transcripts by Seeking Alpha
- How to choose the right insurance carrier for your business
- Real Estate: Prepare your properties to weather what lies ahead
- Technology: Be prepared if part of your global supply chain goes missing
Archives
Recommended Sources
About Pharma Industry
BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.